目的 探究丁苯酞软胶囊联合依达拉奉治疗神经功能障碍的临床疗效。方法 选择2017年1月—2019年1月于西安大兴医院神经内科接受治疗的98例神经功能障碍的患者为研究对象，按照随机数字表法将患者均分为对照组和观察组，每组各49例。对照组患者静滴依达拉奉注射液，应用剂量为30 mg/次，2次/d。观察组在对照组基础上口服丁苯酞软胶囊，2粒/次，3次/d。两组患者治疗2周。观察两组患者的临床疗效，同时比较两组治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分、Barthel指数及简易智能精神状态量表（MMSE）评分。结果 治疗后，观察组治疗总有效率为93.88%，对照组的治疗总有效率为83.67%，两组对比差异存在统计学意义（P<0.05）。经治疗1周及2周后，两组患者NIHSS量表评分较治疗前显著下降（P<0.05），且观察组患者NIHSS评分显著均低于对照组（P<0.05）。治疗后，两组患者Barthel指数和MMSE量表评分均显著提升（P<0.05），且观察组患者Barthel指数及MMSE评分均显著高于对照组（P<0.05）。结论 丁苯酞联合依达拉奉对于神经功能障碍有较好的治疗效果，能显著改善患者的神经功能和生活质量，且不良反应的发生率较低，值得进行临床推广。

Objective To explore the clinical effect of Butylphthalide Soft Capsules combined with edaravone in treatment of neurological dysfunction. Methods A total of 98 patients with neurological dysfunction who were treated in the Department of Neurology, Xi'an Daxing Hospital from January 2017 to January 2019 were selected as the study subjects. According to the random number table method, the patients were divided into the control group and the observation group, with 49 patients in each group. Patients in the control group were iv administered with Edaravone Injection at doses of 30 mg/time, twice daily. Patients in the observation group were po administered with Butylphthalide Soft Capsules on the basis of control group, two grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy in two groups was observed, and the NIHSS score, Barthel index, and MMSE score before and after treatment were compared. Results After treatment, the total effective rate was 93.88% in the observation group, and 83.67% in the control group, with statistically significant difference between two groups (P<0.05). After one and two weeks of treatment, the NIHSS scale score in two groups was significantly lower than that before treatment (P<0.05), and the NIHSS score in the observation group was significantly lower than that of the control group (P<0.05). After treatment, the Barthel index and MMSE scale score in two groups were significantly improved (P<0.05), and the Barthel index and MMSE score in the observation group were significantly higher than those in the control group (P<0.05). Conclusion Butylphthalide combined with edaravone has a good therapeutic effect on neurological dysfunction, can significantly improve the neurological function and quality of life of patients, and the incidence of adverse reactions is low, which is worthy of clinical promotion.

R971